Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin and Gemcitabine in Sarcomatoid Renal Cell Carcinoma
NCT00068393Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Feb 2004
- Primary completion
- Jun 2009
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin and gemcitabine in sarcomatoid renal cell carcinoma (sRCC), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Response Rate by Solid Tumor Response Criteria (RECIST). Started Feb 2004; status: completed.
02
Drugs
pegylated liposomal doxorubicingemcitabine
03
Conditions
sarcomatoid renal cell carcinoma (sRCC)
Beyond the preview
Go deeper on NCT00068393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068393.